SLC5A2 and ventricular tachycardia: Although current evidence supports that SGLT2 inhibitors reduce the risk of ventricular tachycardia, and atrial fibrillation in patients with or without T2DM, this is limited to meta-analyses, while the mechanisms are not well elucidated.